1. Defining the clinical course of multiple sclerosis: Results of an international survey
2. Defining the clinical course of multiple sclerosis: The 2013 revisions
3. Food and Drug Administration (USA). Ocrelizumab Summary Review; 2017. Available at: accessdata.fda.gov/drugsatfda_docs/nda/2017/761053Orig1s000SumR.pdf. Accessed November 23, 2019.
4. European Medicines Agency. Summary of Opinion—Ocrevus; 2017. Available at: ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ocrevus_en.pdf. Accessed September 23, 2019.
5. European Medicines Agency. Summary of Opinion—Mayzent; 2019. Available at: ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mayzent_en.pdf. Accessed September 23, 2019.